Results of a retrospective study presented during the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) looked at the effect of immune checkpoint inhibitors (immunotherapy, e.g. nivolumab, ipilimumab, pembrolizumab) on the survival of patients with metastatic non-clear cell renal cell carcinoma (RCC) compared to targeted therapy with vascular endothelial growth factor (VEGF) […]
Data from the CheckMate-920 study on the safety and effectiveness of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC) was presented at the virtual American Society for Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco this weekend. CheckMate-920 is a community-based, phase IIIb/IV clinical trial of nivolumab plus […]
The recent phase II KEYNOTE-427 study investigated the efficacy and safety of pembrolizumab in patients with untreated advanced clear cell renal cell carcinoma (RCC) and non-clear cell RCC. Pembrolizumab is a type of immunotherapy (an immune checkpoint inhibitor called a programmed death 1 inhibitor, PD-1), which has been shown to be effective in untreated patients […]
Dr Sumanta (Monty) Pal, Clinical Professor and Co-Director of the Kidney Cancer Programme, at the City of Hope Hospital, California talks about the changes in the management of renal cell carcinoma (RCC) over the past decade. He talks about combination treatments such as nivolumab with ipilimumab, which shows the potential for a complete response in […]
This article summarises the key breakthroughs in the treatment of renal cell carcinoma (RCC) in 2020, including a new first-line VEGF-TKI and immunotherapy combination (cabozantinib plus nivolumab) and immunotherapy as a new standard of treatment for patients with non−clear cell RCC and sarcomatoid RCC. Read more in Practice Update here Watch a video interview on […]
In this video interview, Dr Monty Pal from the City of Hope Hospital in California talks about a subset of patients in the COSMIC-021 (cohort 10) with non-clear cell RCC, such as papillary renal cell carcinoma (RCC) and chromophobe RCC. Response rates exceeded 30%, which are very promising findings compared to TKIs alone. However, not […]
Treating non-clear cell renal cell carcinoma (RCC) is challenging because these diseases are rare, and so far there are no effective treatments for this group of patients. Non-clear cell RCC is currently treated in a similar way to clear cell RCC. In a phase 2 clinical trial, 31 patients with non-clear cell RCC were treated […]
Most people have a type of kidney cancer called clear cell renal cell carcinoma (RCC). A recent study has shown that people with clear cell RCC have a better response to tremelimumab (an anti-CTLA-4 antibody) compared with patients with non-clear cell RCC following a procedure called cryoablation (freezing the tumour using probes through the skin). […]
In this video interview with Dr Monty Pal from the City of Hope Hospital in California, treatment of non-clear cell renal cell carcinoma (RCC) with a combination of cabozantinib plus atezolizumab is discussed. Most research is focussed on clear cell RCC; however, non-clear cell RCC accounts for about 25% of all RCC diagnoses and usually […]
Non-clear cell renal cell carcinoma (RCC) accounts for about 25% of all RCC diagnoses and usually has worse outcomes than clear cell RCC. Both cabozantinib and immune checkpoint inhibitors have shown preliminary activity in non-clear cell RCC. Cabozantinib appears to enhance the response to immune checkpoint inhibitors and has shown encouraging results in combination with […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
